All Stories

  1. Knockdown of stem cell regulator Oct4A in ovarian cancer reveals cellular reprogramming associated with key regulators of cytoskeleton-extracellular matrix remodelling

    Article • Scientific Reports, April 2017, Nature

    George Kannourakis

  2. Early treatment intensification with R-ICE and 90Y-ibritumomab tiuxetan (Zevalin)-BEAM stem cell transplantation in patients with high-risk diffuse large B-cell lymphoma patients and positive interim PET after 4 cycles of R-CHOP-14

    Article • Haematologica, November 2016, Ferrata Storti Foundation (Haematologica)

    George Kannourakis

  3. Unique proteome signature of post-chemotherapy ovarian cancer ascites-derived tumor cells

    Article • Scientific Reports, July 2016, Nature

    George Kannourakis

  4. Coalition of Oct4A and β1 integrins in facilitating metastasis in ovarian cancer

    Article • BMC Cancer, July 2016, Springer Science + Business Media

    George Kannourakis

  5. Use of Suppression Subtractive Hybridization for Viral Diagnostics

    Article • British Journal Virology, May 2016, Smith and Franklin Academic Publishing Corporation, Ltd, UK

    George Kannourakis

  6. Evaluation of response from axitinib per Response Evaluation Criteria in Solid Tumors versus Choi criteria in previously treated patients with metastatic renal cell carcinoma

    Article • OncoTargets and Therapy, May 2016, Dove Medical Press

    George Kannourakis, Louise Nott

  7. Collaboration of Epithelial Mesenchymal Transition and Cancer Stem Cells: Sinister Routes for Chemoresistant Recurrent Ovarian Cancer

    Article • March 2016, Bentham Science Publishers

    George Kannourakis

  8. Observation versus late reintroduction of letrozole as adjuvant endocrine therapy for hormone receptor-positive breast cancer (ANZ0501 LATER): an open-label randomised, controlled trial

    Article • Annals of Oncology, February 2016, Oxford University Press (OUP)

    George Kannourakis

  9. Resolution of norfloxacin-induced acute liver failure afterN-acetylcysteine therapy: further support for the use of NAC in drug-induced ALF?

    Article • BMJ Case Reports, January 2016, BMJ

    George Kannourakis

  10. An emerging role for immune regulatory subsets in chronic lymphocytic leukaemia

    Article • International Immunopharmacology, October 2015, Elsevier

    George Kannourakis

  11. Suppression subtractive hybridization method for the identification of a new strain of murine hepatitis virus from xenografted SCID mice

    Article • Archives of Virology, September 2015, Springer Science + Business Media

    George Kannourakis

  12. EVERSUN: a phase 2 trial of alternating sunitinib and everolimus as first-line therapy for advanced renal cell carcinoma

    Article • Annals of Oncology, February 2015, Oxford University Press (OUP)

    George Kannourakis

  13. Polyclonal T-Cells Express CD1a in Langerhans Cell Histiocytosis (LCH) Lesions

    Article • PLoS ONE, October 2014, PLOS

    George Kannourakis

  14. Axitinib versus sorafenib in advanced renal cell carcinoma: subanalyses by prior therapy from a randomised phase III trial

    Article • British Journal of Cancer, May 2014, Nature

    George Kannourakis

  15. P0211 EVERSUN: A phase 2 trial of everolimus alternating with sunitinib as first-line therapy for advanced renal cell carcinoma (ANZUP Trial 0901)

    Article • European Journal of Cancer, May 2014, Elsevier

    George Kannourakis

  16. Acute Exercise Leads to Regulation of Telomere-Associated Genes and MicroRNA Expression in Immune Cells

    Article • PLoS ONE, April 2014, PLOS

    George Kannourakis

  17. Neoadjuvant chemotherapy with sequential anthracycline–docetaxel with gemcitabine for large operable or locally advanced breast cancer: ANZ 0502 (NeoGem)

    Article • The Breast, April 2014, Elsevier

    George Kannourakis

  18. Circulating biomarkers and outcomes in a single-arm phase II trial of first-line sunitinib alternating with everolimus for advanced renal cell carcinoma (aRCC): EVERSUN ANZUP trial 0901.

    Article • Journal of Clinical Oncology, February 2014, American Society of Clinical Oncology (ASCO)

    George Kannourakis

  19. EVERSUN: A phase II trial of everolimus alternating with sunitinib as first-line therapy for advanced renal cell carcinoma (aRCC) (ANZUP trial 0901).

    Article • Journal of Clinical Oncology, February 2014, American Society of Clinical Oncology (ASCO)

    George Kannourakis

  20. P3-14-28: ANZ 0502 NeoGem: A Phase II Trial Evaluating the Efficacy and Safety of Epirubicin and Cyclophosphamide Followed by Docetaxel with Gemcitabine (+ Trastuzumab If HER2 Positive) as Neoadjuvant Chemotherapy for Women with Large Operable or Local...

    Article • Cancer Research, December 2011, American Association for Cancer Research (AACR)

    George Kannourakis

  21. A cryptic deletion in 5q31.2 provides further evidence for a minimally deleted region in myelodysplastic syndromes

    Article • Cancer Genetics, April 2011, Elsevier

    George Kannourakis

  22. Neutrophil elastase mutations and risk of leukaemia in severe congenital neutropenia

    Article • British Journal of Haematology, November 2007, Wiley

    George Kannourakis

  23. The Severe Chronic Neutropenia International Registry: 10-Year Follow-up Report

    Article • Supportive Cancer Therapy, July 2006, Elsevier

    George Kannourakis

  24. Three Cases of Activation of Cutaneous Squamous-cell Carcinoma During Treatment with Prolonged Administration of Rituximab

    Article • Clinical Oncology, March 2006, Elsevier

    George Kannourakis

  25. Severe chronic neutropenia: Treatment and follow-up of patients in the Severe Chronic Neutropenia International Registry

    Article • American Journal of Hematology, January 2003, Wiley

    George Kannourakis

  26. A time to kill: viral manipulation of the cell death program

    Article • Journal of General Virology, July 2002, Society for General Microbiology

    George Kannourakis

  27. Glycogen storage disease

    Article • Seminars in Hematology, April 2002, Elsevier

    George Kannourakis

  28. THE INTERNATIONAL REGISTRY ON SEVERE CHRONIC NEUTROPENIA (SCNIR)

    Article • Pediatric Research, June 1999, Nature

    George Kannourakis

  29. THE INTERNATIONAL REGISTRY ON SEVERE CHRONIC NEUTROPENIA (SCNIR)

    Article • Pediatric Research, June 1999, Nature

    George Kannourakis

  30. IMPROVED SURVIVAL FROM GRANULOCYTE-COLONY STIMULATING FACTOR THERAPY FOR CONGENITAL NEUTROPENIA UNMASKS PREDISPOSITION TO MYELODYSPLASIA AND ACUTE MYELOID LEUKEMIA

    Article • Pediatric Research, June 1999, Nature

    George Kannourakis

  31. IMPROVED SURVIVAL FROM GRANULOCYTE-COLONY STIMULATING FACTOR THERAPY FOR CONGENITAL NEUTROPENIA UNMASKS PREDISPOSITION TO MYELODYSPLASIA AND ACUTE MYELOID LEUKEMIA

    Article • Pediatric Research, June 1999, Nature

    George Kannourakis

  32. Improved Survival From Granulocyte-Colony Stimulating Factor Therapy for Congenital Neutropenia Unmasks Predisposition to Myelodysplasia and Acute Myeloid Leukemia

    Article • Pediatric Research, May 1999, Nature

    George Kannourakis

  33. Incidence of Secondary Leukemias in Patients With Severe Chronic Neutropenias

    Article • Pediatric Research, May 1999, Nature

    George Kannourakis

  34. Report on Patients with Shwachman-Diamond Syndrome with Severe Chronic Neutropenia ♦ 751

    Article • Pediatric Research, April 1998, Nature

    George Kannourakis

  35. Perivascular T Cells Express the Pro-Inflammatory Chemokine RANTES mRNA in Multiple Sclerosis Lesions

    Article • Scandinavian Journal of Immunology, August 1997, Wiley

    George Kannourakis

  36. Leukemia inhibitory factor and interleukin‐6 are produced by diseased and regenerating skeletal muscle

    Article • Muscle & Nerve, October 1996, Wiley

    George Kannourakis

  37. Leukemia inhibitory factor and interleukin-6 are produced by diseased and regenerating skeletal muscle

    Article • Muscle & Nerve, October 1996, Wiley

    George Kannourakis

  38. EWS/FLI-1 Fusion Transcript Detection and MIC2 Immunohistochemical Staining in the Diagnosis of Ewing's Sarcoma

    Article • Fetal and Pediatric Pathology, May 1996, Informa Healthcare

    George Kannourakis

  39. EWS/FLI-1 Fusion Transcript Detection and MIC2 Immunohistochemical Staining in the Diagnosis of Ewing's Sarcoma

    Article • Pediatric Pathology & Laboratory Medicine, January 1996, Taylor & Francis

    George Kannourakis

  40. Cytogenetic and DNA analysis of two neuroectodermal tumors without a simple t(11;22)

    Article • Cancer Genetics and Cytogenetics, August 1995, Elsevier

    George Kannourakis

  41. Soluble antigen can cause enhanced apoptosis of germinal-centre B cells

    Article • Nature, May 1995, Nature

    George Kannourakis

  42. bcl-2 transgene expression can protect neurons against developmental and induced cell death.

    Article • Proceedings of the National Academy of Sciences, May 1995, Proceedings of the National Academy of Sciences

    George Kannourakis

  43. Viable bone marrow stromal cells are required for the in vitro survival of B-cell precursor acute lymphoblastic leukemic cells

    Article • Leukemia Research, February 1995, Elsevier

    George Kannourakis

  44. Expression of the cytokine rantes in multiple sclerosis lesions

    Article • Journal of Neuroimmunology, October 1994, Elsevier

    George Kannourakis

  45. The biology of erythropoietin and its role in the anaemia of prematurity

    Article • Journal of Paediatrics and Child Health, August 1994, Wiley

    George Kannourakis

  46. Human bone marrow stromal cell contact and soluble factors have different effects on the survival and proliferation of paediatric B-lineage acute lymphoblastic leukaemic blasts

    Article • Leukemia Research, May 1994, Elsevier

    George Kannourakis

  47. Dose-intensive cyclophosphamide with etoposide and vincristine for pediatric solid tumors: a phase I/II pilot study by the Australia and New Zealand Childhood Cancer Study Group.

    Article • Journal of Clinical Oncology, March 1994, American Society of Clinical Oncology (ASCO)

    George Kannourakis

  48. Measurement of the growth parameters of precursor B-acute lymphoblastic leukaemic cells in co-culture with bone marrow stromal cells; Detection of two CD10 positive populations with different proliferative capacities and survival

    Article • Leukemia Research, January 1994, Elsevier

    George Kannourakis

  49. A novel approach to the measurement of different in vitro leukaemic cell growth parameters: The use of PKH GL fluorescent probes

    Article • Leukemia Research, October 1993, Elsevier

    George Kannourakis

  50. A human complement-fixing monoclonal anti-human lymphocyte antibody of rat origin

    Article • Immunology and Cell Biology, February 1988, Nature

    George Kannourakis

  51. Activated killer cell lymphoma: An erythrophagocytic syndrome simulating histiocytic medullary histiocytosis

    Article • Pathology, January 1988, Elsevier

    George Kannourakis

  52. Transgenic mice expressing a hemopoietic growth factor gene (GM-CSF) develop accumulations of macrophages, blindness, and a fatal syndrome of tissue damage

    Article • Cell, November 1987, Elsevier

    George Kannourakis

  53. Osmotic fragility of leukaemic and normal lymphocytes

    Article • Pathology, January 1978, Elsevier

    George Kannourakis